scholarly journals BILATERAL BREAST CANCER - CASE SERIES

2020 ◽  
pp. 1-2
Author(s):  
N. Murugesan ◽  
M. Amudhan ◽  
M.S. Viswanathan ◽  
Bhanumati Bhanumati ◽  
Muthuraj Muthuraj ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma ◽  
Bilateral Breast Cancer ◽  
Case Series ◽  
Breast Cancer Case ◽  
Metastatic Carcinoma ◽  
Primary Carcinoma ◽  
Cancer Case ◽  
Infiltrating Ductal Carcinoma ◽  
Secondary Lesion

This is a presentation of four rare and interesting cases of bilateral breast cancer. The cases vary from Synchronous double primary carcinoma breast, bilateral infiltrating ductal carcinoma, bilateral synchronous metastatic carcinoma and metachronous breast carcinoma. The incidence of developing either primary or metastatic carcinoma in the other breast is increased in patients who already have carcinoma in one side and mammography contributes greatly to the detection of these lesions. (1) It is of significant prognostic value and important in deciding the clinical management based on the classification whether it is a primary or a secondary lesion.

Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature

2016 ◽  
Vol 29 (2) ◽  
pp. 113-117 ◽  
Author(s):  
Dana Bielopolski ◽  
Ella Evron ◽  
Osnat Moreh-Rahav ◽  
Michal Landes ◽  
Salomon M. Stemmer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Case Series ◽  
Breast Cancer Case ◽  
Cancer Case ◽  
Review Of The Literature

scholarly journals BMET-11. DURAL METASTASES FROM BREAST CANCER - CASE SERIES

2016 ◽  
Vol 18 (suppl_6) ◽  
pp. vi28-vi28
Author(s):  
David Macdonald ◽  
Joseph Megyesi ◽  
Kylea Potvin
Keyword(s):  
Breast Cancer ◽  
Case Series ◽  
Breast Cancer Case ◽  
Cancer Case ◽  
Dural Metastases

scholarly journals The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature

2021 ◽  
Vol 11 ◽  
Author(s):  
Giovanna Garufi ◽  
Luisa Carbognin ◽  
Armando Orlandi ◽  
Antonella Palazzo ◽  
Giampaolo Tortora ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Clinical Trials ◽  
Scientific Evidence ◽  
Case Series ◽  
Metastatic Breast ◽  
Signs And Symptoms ◽  
Breast Cancer Case ◽  
Clinical History ◽  
Cancer Case

The efficacy and safety of the combination of endocrine therapy (ET) and CDK4/6 inhibitors for patients with hormone receptor (HR)-positive HER2-negative metastatic breast cancer (BC) presenting with visceral crisis or life-threatening conditions represent a challenge for daily clinical practice. Indeed, the peculiarity of this clinical presentation (signs and symptoms of rapidly progressive disease) does not allow to include such patients in a trial aiming for drug approval. On the basis of the scientific evidence available so far, chemotherapy represents the standard of care according to guidelines, on the basis of the more rapid activity in comparison with ET alone. Besides, the combination of ET and CDK4/6 inhibitors have demonstrated in clinical trials to have clinically impactful activity in a short time, thus suggesting a potential role in advanced tumors that require rapid response. Herein, we report the clinical history of a young woman with HR-positive HER2-negative metastatic BC and a pancytopenia due to carcinomatosis of the bone marrow receiving letrozole and leuprorelin plus the CDK4/6 inhibitor palbociclib, who significantly derived clinical benefit from treatment. Considering that these peculiar cases are excluded from clinical trials, the estimation of the magnitude of the benefit of the newer ET combination may potentially represent a practical question for large case series and real-world studies.

scholarly journals Tissue microarrays for testing basal biomarkers in familial breast cancer cases

2007 ◽  
Vol 125 (4) ◽  
pp. 226-230 ◽  
Author(s):  
Rozany Mucha Dufloth ◽  
Irina Matos ◽  
Fernando Schmitt ◽  
Luiz Carlos Zeferino
Keyword(s):  
Breast Cancer ◽  
Tissue Microarray ◽  
Familial Breast Cancer ◽  
Case Series ◽  
Breast Cancer Case ◽  
Cancer Case ◽  
Microarray Technology ◽  
Sporadic Cancer ◽  
Familial Tumors ◽  
Cancer Phenotype

CONTEXT AND OBJECTIVE: The proteins p63, p-cadherin and CK5 are consistently expressed by the basal and myoepithelial cells of the breast, although their expression in sporadic and familial breast cancer cases has yet to be fully defined. The aim here was to study the basal immunopro-file of a breast cancer case series using tissue microarray technology. DESIGN AND SETTING: This was a cross-sectional study at Universidade Estadual de Campinas, Brazil, and the Institute of Pathology and Mo-lecular Immunology, Porto, Portugal. METHODS: Immunohistochemistry using the antibodies p63, CK5 and p-cadherin, and also estrogen receptor (ER) and Human Epidermal Receptor Growth Factor 2 (HER2), was per-formed on 168 samples from a breast cancer case series. The criteria for identifying women at high risk were based on those of the Breast Cancer Linkage Consortium. RESULTS: Familial tumors were more frequently positive for the p-cadherin (p = 0.0004), p63 (p < 0.0001) and CK5 (p < 0.0001) than was sporadic cancer. Moreover, familial tumors had coexpression of the basal biomarkers CK5+/ p63+, grouped two by two (OR = 34.34), while absence of coexpression (OR = 0.13) was associ-ated with the sporadic cancer phenotype. CONCLUSION: Familial breast cancer was found to be associated with basal biomarkers, using tissue microarray technology. Therefore, characterization of the familial breast cancer phenotype will improve the understanding of breast carcinogenesis.

scholarly journals The Role of <sup>18</sup>F-FDG-PET/CT in the Management of Patients with High-Risk Breast Cancer: Case Series and Guideline Comparison

2014 ◽  
Vol 04 (03) ◽  
pp. 35-41
Author(s):  
Ben F. Bulten ◽  
Marie J. de Haas ◽  
Haiko J. Bloemendal ◽  
Adriaan J. van Overbeeke ◽  
Jan Paul Esser ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Case Series ◽  
Breast Cancer Case ◽  
Cancer Case ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
High Risk Breast Cancer ◽  
High Risk Breast ◽  
Risk Breast Cancer

THERAPEUTICAL SURGICAL CHOICES FOR BILATERAL BREAST CANCER- CASE PRESENTATION

2003 ◽  
Vol 13 (Suppl 1) ◽  
pp. 88.1-88
Author(s):  
P. C. Bratila ◽  
O. Nicodin ◽  
N. Niculescu ◽  
M. Serban ◽  
E. Raducea Barbulea ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bilateral Breast Cancer ◽  
Breast Cancer Case ◽  
Cancer Case ◽  
Case Presentation ◽  
Surgical Choices

Infiltrating ductal carcinoma of male breast: A retrospective study

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10753-10753
Author(s):  
T. Puri ◽  
M. Malik ◽  
G. Gunabushanam ◽  
D. N. Sharma ◽  
P. K. Julka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Ductal Carcinoma ◽  
Lung Metastases ◽  
Bilateral Breast Cancer ◽  
Radical Mastectomy ◽  
Male Breast ◽  
Single Institution ◽  
Infiltrating Ductal Carcinoma ◽  
Progesterone Receptor Positivity

10753 Background: A single-institution retrospective review of the clinical presentation, treatment and outcome of male breast infiltrating ductal carcinoma (IDC). Methods: Case records of 25 male patients with a histological diagnosis of infiltrating ductal carcinoma (IDC) of breast who were treated in a single institution between 1997 to 2004 were retrospectively reviewed. Results: Patients presented at a mean age of 56 years (range, 34 to 80 years). The presenting complaint was a painless lump in the breast in all the cases. The right breast was involved in 13 cases (52%). There were no cases of bilateral breast cancer. The distribution of patients by stage at presentation are: stage IIA (24%), IIB (20%), IIIA (8%), IIIB (40%), and IV (8%). None of the patients presented with stage I disease. One patient had lung metastases at presentation. Rest of the 24 patients (96%) underwent surgery (modified radical mastectomy, 22 patients; simple mastectomy, 2 patients). Fifteen patients (60%) received adjuvant local radiotherapy. All patients received adjuvant chemotherapy: As per departmental protocol, those presenting before 2000 were treated using a regimen of Cyclophosphamide, Adriamycin and 5-Fluorouracil. After 2000, Ebirubicin was substituted for Adriamycin. Three patients were further administered Docetaxel, the indication being disease progression after first line adjuvant chemotherapy. Estrogen & Progesterone receptor positivity was 64% and 60% respectively. Hormonal therapy (Tamoxifen 14 patients, Anastrozole 2 patients) was administered in these patients. The length of follow-up from time of presentation ranged from 4 to 100 months (mean, 28 months; median, 13 months). At the time of analysis, of the 25 patients, 18 patients (72%) remain disease free, whereas 7 patients (28%) developed progressive disease. Median survival was not reached at the present time. Conclusions: Breast cancer, specifically IDC tends to present at a later stage in males, due to a lack of screening for the disease. In the present series, as a result of the advanced stage of initial presentation, all patients received adjuvant chemotherapy. There is a need to improve awareness among males, of the possibility of a painless breast lump being the first symptom of an underlying malignancy. No significant financial relationships to disclose.

scholarly journals The radiation therapy in occult primary breast cancer: case series

Mastology ◽  
2018 ◽  
Vol 28 (s1) ◽  
pp. 33-33
Author(s):  
Ana Flávia de Paula Guerra Campedelli ◽  
◽  
Nilceana Maya Aires Freitas ◽  
Thais Franco Simionatto ◽  
Nathalya Ala Yagi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Primary Breast Cancer ◽  
Case Series ◽  
Breast Cancer Case ◽  
Cancer Case
Sign in / Sign up

Export Citation Format

Share Document